Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 4,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Blood samples collected Clear all

Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography, Questionnaire Administration; Procedure · Biological · Drug + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders, Myelodysplastic Syndromes
Interventions: blood draw, bone marrow procedure, or tissue biopsy; Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 532
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more

Conditions: Astrocytoma, Glioma, Oligodendroglioma
Interventions: Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine, Trivalent Influenza Vaccine; Biological · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Medical Device Usage and Evaluation, Physical Performance Testing, Positron Emission Tomography, Survey Administration; Procedure · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 225
States / cities: Fort Smith, Arkansas • Aurora, Colorado • Boulder, Colorado + 160 more

Conditions: Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions: Abemaciclib, Biopsy Procedure, Biospecimen Collection, Olaparib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 22 more

Conditions: Lyme Disease
Interventions: Stool and blood collection; Other
Lead sponsor: FlightPath Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hodgkin's Disease
Interventions: G-CSF Plus Plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ketogenic Dieting, Ketoses, Metabolic, Ketosis
Interventions: Well-formulated Ketogenic Diet; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 30 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Pulmonary Diseases
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3,087 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma, Skin Melanoma
Interventions: self-administered questionnaire and blood draw, health questionnaire, blood draw and skin exam; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne
Interventions: Skin biopsy, Blood draw; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Melanoma
Interventions: High-performance liquid chromatography-tandem mass spectrometry assays; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 100 Years
Enrollment: 90 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Arthrogryposis, Craniofacial Abnormalities
Interventions: Lactate, Glucose, and Adenosine Triphosphate Blood Levels, Physiological Stress Test, Functional Enquiry Form, Strength, Joint ROM, Girth and Length Measurements, Study Physical Examination, Observational Gait Analysis, Mental Health Interview; Other · Procedure
Lead sponsor: Freeman-Sheldon Research Group, Inc.; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Buckhannon, West Virginia

Conditions: Liver Damage
Interventions: The Medtronic Portable Bypass System (PBS®); Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Syncytial Virus Infections
Interventions: Not listed
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 21 Months
Enrollment: 344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Omaha, Nebraska • Cleveland, Ohio

Conditions: Colo-rectal Cancer
Interventions: Blood Sample Collection; Other
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 45 Years to 49 Years
Enrollment: 871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 37
States / cities: Phoenix, Arizona • Camarillo, California • Laguna Hills, California + 32 more

Conditions: Postexercise Hypotension
Interventions: Aerobic Exercise, alpha-FMH, Resistance and Aerobic Exercise, Antihistamine; Behavioral · Drug
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Prostate Cancer, Localized Prostate Cancer
Interventions: [18F] DIHYDRO-TESTOSTERONE, PET scan, MRI, Blood draw; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 79 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Testicular Germ Cell Tumor
Interventions: Clinical Stage I Disease, Clinical Stage I with relapse, CSII Disease; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Male only
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 2 more

Conditions: Congestive Heart Failure
Interventions: Heart Self Care Tracker, Heart Care Self Tracker; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Functional Gastrointestinal Disorders, Hypermobile Ehlers-Danlos Syndrome, Postural Orthostatic Tachycardia Syndrome, Autonomic Nervous System Disease, Autonomic Nervous System Imbalance
Interventions: Percutaneous vagal nerve stimulation (pVNS) device, Acoustic vagal nerve stimulation (aVNS) treatment; Device · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 10 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Pathogenesis of Hematologic Malignancies

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Biomarker Study of Previously Treated Lyme Disease Volunteers in Comparison to Healthy Volunteers

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Ketogenic Diet Health and Longevity

Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases

Differential Risks for Melanoma: p16 and DNA Repair

Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris

Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma

Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions

Hypothermic Machine Preservation-Phase 2

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.

Histamine as a Molecular Transducer of Adaptation to Exercise

[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer

MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

Heart Failure Patient Self-Management Web Portal Pilot Study

Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome